Engflag

Albumar

Quick links to important sections

Albumar

Albumar_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Albumar

Property Description
Active ingredient Albendazole
Form Tablets (chewable/film-coated) and Oral Suspension
Pharmacological class Antihelminthic (Anthelmintic) / Benzimidazole
Common use Elimination of parasitic worm infections
Origin Synthetic chemical compound

What is Albumar and Its Identity?

Albumar is a prescription-only medication whose active component is the substance Albendazole, a synthetic compound classified as a benzimidazole antihelminthic agent. Albendazole is recognized as an essential medicine, reflecting its sustained and clinically recognized global importance in treating parasitic infections.

Albendazole is differentiated by its systemic absorption, which helps it target certain tissue-dwelling parasites more effectively than some structurally similar drugs. In clinical applications, Albendazole is noted for its efficacy levels against specific soil-transmitted helminths compared to related agents.

Composition, Origin, and Available Forms

Its active ingredient, Albendazole, is a purely synthetic chemical compound, ensuring a consistent molecular structure. It is administered via the oral route and is available as tablets and an oral suspension. The availability of the oral suspension is a practical feature, expanding the target patient group to include individuals with swallowing difficulties.

The medication is a single-ingredient product, with the therapeutic effect relying on the systemic conversion of Albendazole into its active form, Albendazole sulfoxide. This metabolite's ability to act systemically is what defines the drug as a broad-spectrum dewormer.

What is the General Purpose of This Type of Medicine?

The general purpose of Albumar is to function as a broad-spectrum dewormer, helping to eliminate various parasitic worm infections in the body, such as hookworm or roundworm. The drug works by selectively disrupting the parasite's internal cell structures, specifically its microtubules, which are essential for its function and glucose uptake. This structural interference results in the organism being starved of energy, leading to the death of the parasite and subsequent relief of the parasitic burden.

Regulatory References

  1. NIH StatPearls on Albendazole

What side effects are possible with Albumar?

Possible side effects and safety information

The safety profile for Albumar (Albendazole) is classified by regulatory documents, distinguishing between commonly expected reactions and rare, serious adverse events, predominantly associated with prolonged systemic use.

Adverse Reaction Scope

Adverse reactions are organized by the likelihood of occurrence and the organ system affected, as documented in official government labeling.

Classification Examples of Officially Listed Adverse Reactions
Common Elevated hepatic enzymes, headache, and upper gastrointestinal symptoms (e.g., nausea, abdominal pain).
Uncommon Dizziness, vertigo, itchiness (pruritus), and skin rashes.
Rare Hypersensitivity reactions, low red cell count, and severe hepatic abnormalities.

The main System-Organ Classes involved include Hepatobiliary Disorders, Blood and the Lymphatic System Disorders, and the Nervous System.

Serious Adverse Reactions and Safety Constraints

Regulatory sources specify rare but clinically significant risks, primarily linked to high-dose systemic therapy. These include bone marrow suppression (e.g., pancytopenia and agranulocytosis), severe hepatic abnormalities, and severe cutaneous reactions such as Stevens-Johnson syndrome.

Safety Restrictions: Albumar is contraindicated in pregnancy due to potential fetal harm, and women of childbearing potential must use effective contraception during and for one month after therapy. Patients with pre-existing hepatic impairment require increased monitoring due to a heightened risk of bone marrow suppression. For all patients on systemic therapy, the label mandates monitoring of blood counts and liver enzymes at specified intervals.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that the primary concern in an Albendazole overdose is the potential for severe, life-threatening organ toxicity. Fatalities have been reported due to bone marrow suppression, leading to conditions like pancytopenia or agranulocytosis. Other documented severe outcomes include acute liver failure and severe neurological manifestations, such as seizures and increased intracranial pressure.

Immediate medical help or contact with a Poison Control center is required in all cases of suspected overdose. The official prescribing information mandates specific action: therapy must be discontinued if blood counts show clinically significant decreases or if hepatic enzymes rise above a specific level (more than twice the upper limit of normal).

Because no specific antidote is known, the management of overdose is strictly limited to symptomatic and supportive care. If neurological symptoms occur, regulators state that appropriate steroid and anticonvulsant therapy must be initiated immediately. Patients with pre-existing liver disease are considered to be at an increased risk for bone marrow suppression and warrant closer monitoring.

This profile defines the overdose risk by the necessity of mandated monitoring and the immediate cessation of the medicine upon reaching predefined toxicity thresholds.

Therapeutic Uses of Albumar

This medicine is generally used to manage conditions presenting with systemic or localized discomfort caused by parasitic infections. It is considered relevant for easing symptoms related to systemic imbalance and is applied across domains relevant for addressing high-risk or serious conditions, such as parasitic cysts in the brain and major organs, as well as common intestinal parasitic worm infections, including roundworm, pinworm, and hookworm.

This medicine may be part of symptomatic management during phases when symptoms become more noticeable.

"This medicine helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load."

Key Uses and Patient Benefit

In clinical scenarios, this medicine is commonly used to help with symptoms of increased neurological activity (like seizures) and physical discomfort associated with gastrointestinal distress. It provides supportive relief from symptoms that interfere with daily functioning, assisting with maintaining functional stability when symptoms escalate temporarily by addressing the underlying parasitic cause.

Quick Fact: Relief for symptoms related to physical discomfort in conditions where functional stability becomes affected.

Regulatory References

  1. NIH MedlinePlus overview on Albendazole

Eligibility and Restrictions for Use

The official regulatory documents define strict criteria for patient eligibility for Albumar (Albendazole). These rules govern who is allowed to use the medicine and who is formally prohibited from using it.

Contraindicated Populations (Must Not Use)

  • Hypersensitivity: Individuals with a known allergy or history of hypersensitivity to Albendazole or any drug belonging to the benzimidazole class are formally contraindicated.
  • Pregnancy: The medicine is contraindicated in pregnant women due to the risk of fetal harm. Women of childbearing potential are required to obtain a negative pregnancy test before starting treatment and must use effective contraception during and for a specified period after therapy.

Conditional Use and Restricted Eligibility

  • Liver Function: Patients with pre-existing or abnormal hepatic impairment (liver disease) must use the medicine with caution. They require mandated, close monitoring of liver enzyme levels throughout treatment, as specified in regulatory labels.
  • Hematological Function: Patients with a history of bone marrow suppression or low blood cell counts require caution, with regulators mandating periodic monitoring of blood counts.
  • Age-Related Eligibility: The medicine is generally approved for adults and children ge 2 years of age for systemic infections. Use is not established or not recommended for infants under 6 months of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Albumar (Albendazole) documents specific interaction patterns that alter the concentration of its active metabolite, Albendazole sulfoxide, or increase pharmacodynamic risks. Official labeling requires all interaction information to be considered strictly within the context of co-administration.

Documented Exposure-Altering Interactions

Interaction Type Interacting Substance Official Regulatory Outcome
PK Increase Dexamethasone Increases the active metabolite's trough concentrations by approximately 56%.
PK Increase Praziquantel Increases the mean maximum plasma concentration and AUC by about 50%.
PK Decrease Enzyme Inducers (e.g., Rifampicine, Ritonavir) Has the potential to reduce plasma concentrations of the active metabolite.
Substance Interaction Food (Fatty Meal) Significantly increases absorption and bioavailability, a constraint necessary for therapeutic exposure.

Pharmacodynamic and Class Restrictions

Albumar is contraindicated in patients with a known hypersensitivity to the benzimidazole class of compounds. Co-administration with other myelosuppressive agents can result in additive myelosuppression, a documented pharmacodynamic interaction. Additionally, in patients with evidence of extrahepatic biliary obstruction, systemic exposure of the active metabolite is increased and elimination is prolonged, which may affect the clinical relevance of other interactions.

Mechanism of Action

The mechanism of Albumar (Albendazole) is an exquisitely targeted process that leads to the structural and metabolic failure of the parasite.

Molecular Blockade of Cellular Structure

The active metabolite, Albendazole sulfoxide, acts as a specific inhibitor by binding to the beta-tubulin subunit within the helminth's cells. This binding prevents tubulin polymerization, causing the essential cytoplasmic microtubules to degenerate. This cellular structural collapse is an initiating step in the cascade.

Pathway Disruption Leading to Energy Starvation

The loss of functional microtubules critically impairs the parasite's glucose uptake and transport pathway. This metabolic blockade rapidly depletes the organism's glycogen reserves and sharply reduces ATP production. The resulting energy starvation leads to immobilization and functional collapse within the parasite.

Mechanism Limitations Based on Target Activity

The mechanism relies on the target organism maintaining active metabolic processes. Therefore, the mechanism is limited when the target exhibits low metabolic activity, such as in calcified or dormant cyst forms of the parasite, as this restricts the necessary interference with beta-tubulin and energy pathways.

Dosage and Administration Information

How Albumar (Albendazole) Is Used: Official Usage Patterns

This section describes the high-level, standardized administration principles for Albumar.

Administration and Contextual Instructions

The approved route for Albumar is oral, consistent with its availability as tablets and oral suspension. A key administration principle is the requirement to take the medication with food, specifically a fatty meal, to ensure adequate systemic absorption, which is essential when targeting parasites outside the intestinal tract. The tablets may be swallowed whole, chewed, or crushed and mixed with water to facilitate intake.

Dosing is highly dependent on the type of infection:

Indication Type Standard Adult Regimen Duration Pattern
Intestinal/Localized Infections 400 mg as a single oral dose or short course (e.g., 1–3 days). Short-term/Single-dose, sometimes repeated after 2 weeks.
Systemic Tissue Infections 400 mg twice daily for patients ≥ 60 kg. Weight-based dosing applies for smaller patients, up to a maximum of 800 mg/day. Long-term, using defined 28-day dosing cycles separated by a 14-day drug-free interval.

Population and Procedural Rules

Pediatric dosing for common intestinal infections begins at 200 mg for children aged 1 to 2 years. Regarding dose adjustments, no change is specified for renal impairment; however, caution is advised for patients with hepatic impairment. Adherence to the maximum daily dose limit of 800 mg and the specified cyclical pattern for systemic diseases are mandatory procedural constraints.

Recent Clinical Evidence

Research Evidence for Albumar (Albendazole)

This section provides an overview of the official research studies that have investigated Albumar (Albendazole), outlining the types of trials conducted, the specific measures examined, and where evidence limitations exist, strictly avoiding any clinical advice or recommendations.

Evidence for Use in Parenchymal Neurocysticercosis

Research into Albumar was studied for neurocysticercosis (a parasitic infection in the brain tissue) primarily using Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies monitored the medicine in adult and pediatric populations who had viable cysts in the brain tissue. Researchers closely monitored the status and resolution of the parasitic cysts over time using brain imaging. Findings described patterns observed in the studies, including changes in the number of certain types of seizures measured during long-term follow-up periods. Evidence quality varies across studies, and certainty remains low regarding some aspects of the long-term clinical outcomes. Data for non-parenchymal or already calcified cysts are still emerging.

Evidence for Use in Cystic Echinococcosis (Hydatid Disease)

Albumar was studied for cystic echinococcosis, a condition characterized by parasitic cysts in organs like the liver and lungs, using both RCTs and extended observational cohort studies. Studies monitored outcomes related to cyst viability, such as disappearance or significant size reduction of the cysts. Studies report how cyst status evolved in the observed populations, with trials describing varying rates of success (cure or improvement) that may require continuous treatment over many months. There is limited information for long-term outcomes due to the chronic nature of the disease, and follow-up needs to continue for many years to monitor for potential recurrence.

Evidence for Use in Soil-Transmitted Helminth Infections

Research for common intestinal worms (like roundworm and hookworm) involves large-scale Randomized Controlled Trials and extensive meta-analyses. Research describes findings based on microbiological measures observed in the studies, such as the Cure Rate and the Egg Reduction Rate. Studies reported measurements showing high rates for roundworm and hookworm infections. However, research highlights changes measured during the study period for whipworm (Trichuris trichiura) were observed to be lower and less consistent. Subgroup findings are uncertain concerning the efficacy in areas where mass drug administration has been employed for long periods.

Frequently Asked Questions (FAQ)

Common questions about Albumar (FAQ)

Q: Does it make you sleepy?

According to official product information, sleepiness or somnolence is listed as a very common side effect, meaning it may affect more than 1 in 10 people. This is a common effect listed in the regulatory documents.

Q: Can I drink alcohol while taking this medication?

Regulatory documents generally advise against drinking alcohol while using this medicine. Alcohol can increase certain side effects of Albumar, such as sleepiness, dizziness, and decreased concentration. This increase in side effects is important to consider, especially when operating machinery or driving.

Q: What are the common side effects?

Common side effects, which may affect up to 1 in 10 people, include dizziness, sleepiness, blurred vision, dry mouth, weight gain, and constipation. The product information also lists an abnormal feeling or feeling 'drunk' as reported side effects.

Q: Is it safe long-term?

Regulatory warnings address the potential for physical dependence and dependence after repeated use of this medicine. Regulatory documents indicate that when treatment is stopped after a prolonged period, a gradual withdrawal is recommended to help minimize potential side effects.

Q: Can children 2 years old use it?

Official information from regulatory bodies states that there is not enough information to recommend the use of this medicine in children under the age of 18 years. The official product information clarifies that the safety and effectiveness of Albumar have not been established in patients under 18 years of age.

How should Albumar be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Albumar (Albendazole)

Item Official Regulatory Statement
Labeled storage temperature requirements Store at controlled room temperature between mathbf20 C and mathbf25 C (mathbf68 F to mathbf77 F) [3.1].
Light/moisture protection requirements Protect from moisture and store in a cool, dry place [3.5].
Handling requirements Keep from freezing and away from excess heat [3.5].
Packaging-related storage rules Keep the medication in the original container and keep it tightly closed [3.5].
Disposal instructions (as documented) Dispose of unused product or waste material in accordance with local requirements [3.4].
Child-protection storage requirements Keep out of the sight and reach of children [3.4].

Official regulatory documents define the storage profile of Albumar by mandating a specific controlled room temperature range and strictly prohibiting freezing to maintain the product's stability [3.1], [3.5]. The medicine must be stored in its tightly closed, original container to protect it from moisture and heat [3.5]. For disposal, the label requires that unused medicine must not be discarded via wastewater or general household waste; instead, users must follow local waste regulations [3.4].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Albumar found in:

A-Z Index: